We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease‐modifying antirheumatic drugs have influenced the use of leflunomide.
- Authors
Hopkins, Ashley M.; Vitry, Agnes I.; O'doherty, Catherine E.; Proudman, Susanna M.; Wiese, Michael D.
- Abstract
The article focuses on the use of Methotrexate and leflunomide for the treatment of rheumatoid arthritis. Topics discussed include use of biological disease modifying anti-rheumatic drugs (bDMARD) therapy due to inefficiency of conventional DMARD therapy, combination therapy with methotrexate and DMARD and efficacy of leflunomide and cyclosporine.
- Subjects
RHEUMATOID arthritis treatment; LEFLUNOMIDE; DRUG efficacy; METHOTREXATE; RHEUMATOID arthritis; PATIENTS; THERAPEUTICS
- Publication
International Journal of Rheumatic Diseases, 2017, Vol 20, Issue 11, p1795
- ISSN
1756-1841
- Publication type
Article
- DOI
10.1111/1756-185X.12717